|
|
|
|
|
|
|
Medical Pharmacology Chapter 16: Pharmacology of Antipsychotics Drugs
|
|
|
|
|
|
|
Second Generation Antipsychotic Medications
Clozapine
Clozapine occupies a unique and irreplaceable position in psychiatric pharmacology.
Its receptor profile is extraordinarily broad, including antagonism at D1-4, 5-HT2A/2C, muscarinic, histaminergic, and α-adrenergic receptors.
This complex pharmacology underlies both its superior efficacy and its challenging adverse effect profile.
Efficacy in Treatment-Resistant Schizophrenia
The
definitive evidence for clozapine's superior efficacy was established by
Kane et al. (1988) in a landmark double-blind, randomized controlled trial.4
Patients with treatment-resistant schizophrenia, defined by failure of at least three adequate antipsychotic trials, were randomized to clozapine or chlorpromazine.
At 6 weeks, clozapine produced clinically meaningful response in 30% of participants compared to only 4% in the chlorpromazine group.
This remarkable demonstration of efficacy in patients who had been treatment-resistant established clozapine as the gold standard for this indication, and it remains the only antipsychotic with a specific FDA indication for treatment resistant schizophrenia.
Subsequent network meta-analyses have confirmed this superiority:
Leucht et al. (2013)12 and Huhn et al. (2019)13 both identified clozapine as among the most efficacious antipsychotics in overall symptom reduction, though its use is constrained by safety considerations.
Clozapine and Suicidality
Beyond treatment resistance, clozapine is the only psychotropic with an FDA indication for reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder.
This finding was established by the International Suicide Prevention Trial (InterSePT), conducted by Meltzer et al. (2003).6
In this landmark multicenter RCT, clozapine was compared to olanzapine in 980 patients at high risk for suicidal behavior.
Clozapine
significantly reduced suicidal attempts, hospitalizations to prevent
suicide, and the need for rescue interventions, representing the first
prospective evidence that an antipsychotic could reduce suicidality as a
specific, measurable outcome.
Agranulocytosis and Monitoring Requirements
Despite its efficacy, clozapine carries a well-characterized risk of agranulocytosis, a potentially fatal reduction in granulocytes that necessitates mandatory hematological monitoring.
Alvir et al. (1993) established the key epidemiological parameters of this risk in a large U.S. cohort study.5
The cumulative incidence of agranulocytosis was 0.8% at one year.
Risk was highest during the first 6 months of treatment and was significantly elevated in women and in older patients.
These findings directly informed the mandatory ANC (absolute neutrophil count) monitoring program required in the United States.
Other Adverse Effects of Clozapine
Metabolic effects
Clozapine produces the greatest weight gain and metabolic dysregulation of any antipsychotic.
Newcomer (2005) identified clozapine and olanzapine as the agents with the highest risk of clinically significant weight gain, insulin resistance, and dyslipidemia.
Seizures
Dose-dependent risk, occurring in approximately 3–5% of patients at higher doses.
An EEG is not routinely required but seizure prophylaxis may be warranted.
Cardiovascular
Myocarditis (potentially fatal; risk highest in first month) and cardiomyopathy.
Orthostatic hypotension is common, especially during titration.
QTc prolongation is modest.
Anticholinergic
Sialorrhea (paradoxical, likely due to partial M4 agonism), urinary retention, constipation, and cognitive effects.
|
|
|
|
|
|
 |
|
DISCLAIMER
|
